^
    1year
    A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies (clinicaltrials.gov)
    P1, N=37, Recruiting, TransThera Sciences (Nanjing), Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    TT-01488